Streetwise Reports' Article Archives — June 2023 back to current month (15)
Biotech Co. Remains Opportunity for Those With High Risk Tolerance (06/30/2023)
Recently, Antibe Therapeutics released its fiscal 2023 year-end (FQ423) results, which remained inline with expectations, noted an Echelon Capital research note.
Q3: Chen Is Still Bullish on This Precious Metal (06/29/2023)
Asset manager Chen Lin continues to rely heavily on this precious metal. Find out his top picks for the third quarter of 2023.
Telehealth Co. Expands to More Patients, Picks Up Coverage (06/26/2023)
Reliq Health Technologies Inc. continues to pick up more contracts with skilled nursing facilities (SNFs) and other health care groups. Now it also has gotten analyst attention.
New Drug for Bone Growth Disorder Improves Height Velocity (06/21/2023)
Phase 2 trial data at six months are positive in children with achondroplasia, noted a BTIG report.
Biotech Co. Completes Step Toward Psychedelic Treatment for Brain Injuries (06/16/2023)
Algernon Neuro has completed the third stage of its dosage trial for DMT as a treatment for traumatic brain injury. Read on to see how the company expects to take psychedelics into the mainstream.
777% Gain Implied in Analyst's Target Price on Biopharma Co. (06/14/2023)
Results from a Phase 2 trial of this U.S. company's cystic fibrosis drug are due out next month, noted an H.C. Wainwright & Co. report.
Telehealth Co. Expands With Six New Contracts in Three States (06/13/2023)
New contracts are expected to add more than 3,000 new patients to Reliq Health Technologies Inc.'s platform by the first quarter of next year, the company said.
Court Grants Firm Protection From Creditors (06/12/2023)
Despite this development, there are still some ways this Canadian retailer-distributor could salvage some value for shareholders, noted an Echelon Capital Markets report.
Biotech Co. To Exit Health Care Services (06/12/2023)
Friday, Awakn Life Sciences Corp. announced it would be taking focus away from healthcare services and instead concentrate its efforts exclusively on research and development for therapeutics for addiction treatment. Read more to learn what the global addiction treatment market looks like and where the company is headed in the future.
Key Catalyst for US Biopharma Stock on Track for Q4/23 (06/09/2023)
Readout of a Phase 2b trial is expected then, and positive data could support approval of the company's drug candidate, noted an H.C. Wainwright & Co. report.
Medical Device Co. Completes Merger in Q1/23 (06/08/2023)
Due to the acquisition, the U.S.-based firm generated 844% more revenue during the quarter than it did a year earlier, noted a Ladenburg Thalmann report.
Healthcare Tech Firm Grows Revenue 10% YOY in Q1/23 (06/05/2023)
This positive start to 2023 bodes well for the company turning EBITDA positive later this year, which is expected, noted an Echelon Capital Markets report.
FDA Approval, Private Placement Funding Buoy Biotech Firm (06/05/2023)
Krystal Biotech Inc. appears to be picking up steam for the year's second half. The company's Vyjuvek topical gel for treating Dystrophic Epidermolysis Bullosa (DEB) was approved by the FDA on May 19, leading to a major funding announcement.
Telehealth Co. Notches First Profitable Quarter (06/02/2023)
Reliq Health Technologies announces record revenues for the three months ending March 31 and its first profitable quarter after a loss during the same quarter in 2022.
Analyst Says Pharma Co. 'Meaningfully Undervalued' (06/01/2023)
"We continue to view Mindset as meaningfully undervalued," Stefan Quennevill reported in an Echelon Capital Markets research note.
More Archives
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
